TTI-621 binds CD47 on tumor cells and, via its Fc, engages Fc gamma receptors on macrophages to promote antibody-dependent phagocytosis of CD47+ tumor cells. Cells expressing Fc gamma receptor IIb act as effectors, not targets, and are not directly killed by the drug.